Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
Mol Med Rep (2021) 23(6)
To our knowledge, only two previous studies investigated Glx or Glu in the left basal ganglia or striatum in ADHD, reporting an increase of Glx and Glu in children aged 8 years, 10 and a decrease in Glx in both medication naive and medicated adults
Common symptoms include anemia, fatigue, weakness, lightheadedness, pale skin, and neurological issues such as tingling or numbness in the hands and feet, muscle weakness, memory problems, poor appetite, and mood changes